Case Page

 

Case Status:    DISMISSED    
On or around 07/31/2018 (Notice of voluntarily dismissal)

Filing Date: July 10, 2018

According to the Complaint, Foundation Medicine, Inc. ("Foundation Medicine" or the "Company") provides various molecular information products in the United States. The company's molecular information platform includes proprietary methods and algorithms to analyze specimens across various types of cancer, as well as for incorporating that information into clinical care; and offers genomic insights about each patient's individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted therapies and immunotherapies. It provides clinical products, such as FoundationOne for solid tumors; FoundationOne Heme for blood-based cancers, or hematologic malignancies, including leukemia, lymphoma, and sarcomas; Foundation Assay for Circulating Tumor; FoundationFocus CDxBRCA, a diagnostic assay to aid in identifying women with ovarian cancer; and FoundationOne CDx, a diagnostic assay for solid tumors. The company also offers FoundationCORE, a knowledgebase to publish scientific and medical advances, and foster relationships throughout the oncology community.

On June 19, 2018, Roche and the Company jointly announced the Tender Offer. On July 2, 2018, Foundation Medicine filed the 14D-9 with the SEC in connection with the Tender Offer. The 14D-9 was furnished to the Company’s stockholders and solicits the stockholders to tender their shares.

The Complaint alleges that the 14D-9 misrepresents and/or omits material information that is necessary for the
Company’s stockholders to make an informed decision concerning whether to tender their shares, in violation of Sections 14(a) and 20(a) of the Exchange Act.

On July 11, Plaintiff filed an amended Complaint.

This case was voluntarily dismissed on July 31.

COMPANY INFORMATION:

Sector: Healthcare
Industry: Biotechnology & Drugs
Headquarters: United States

SECURITIES INFORMATION:

Ticker Symbol: FMI
Company Market: NASDAQ
Market Status: Public (Listed)

About the Company & Securities Data


"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
COURT: D. Massachusetts
DOCKET #: 18-CV-11435
JUDGE: Hon. Douglas P. Woodlock
DATE FILED: 07/10/2018
CLASS PERIOD START: 06/19/2018
CLASS PERIOD END: 07/10/2018
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. Andrews DeValerio LLP
    265 Franklin Street, Suite 1702, Andrews DeValerio LLP, MA 02110
    617.936.2796 ·
  2. Wolf Haldenstein Adler Freeman & Herz LLP (New York)
    270 Madison Avenue, Wolf Haldenstein Adler Freeman & Herz LLP (New York), NY 10016
    212.545.4600 212.686.0114 · newyork@whafh.com
No Document Title Filing Date
COURT: D. Massachusetts
DOCKET #: 18-CV-11435
JUDGE: Hon. Douglas P. Woodlock
DATE FILED: 07/11/2018
CLASS PERIOD START: 06/19/2018
CLASS PERIOD END: 07/11/2018
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. Andrews DeValerio LLP
    265 Franklin Street, Suite 1702, Andrews DeValerio LLP, MA 02110
    617.936.2796 ·
  2. Wolf Haldenstein Adler Freeman & Herz LLP (New York)
    270 Madison Avenue, Wolf Haldenstein Adler Freeman & Herz LLP (New York), NY 10016
    212.545.4600 212.686.0114 · newyork@whafh.com
No Document Title Filing Date
—Related District Court Filings Data is not available